CHE Stock Analysis: Chemed | NYSE

Hospice Care, Palliative Care, Plumbing, Drain Cleaning

Total Rating 70

Safety 79

Buy Signal 0.51

Medical Care Facilities
Industry Rotation: +4.8

Market Cap: 6.72B
Avg Turnover: 74.2M

Risk 3d forecast

Volatility25.1%

VaR 5^th Pctl3.84%

VaR vs Median-5.55%

Reward TTM

Sharpe Ratio0.50

Rel. Str. IBD73.5

Rel. Str. Peer Group50

Character TTM

Beta0.155

Beta Downside0.260

Hurst Exponent0.458

Drawdowns 3y

Max DD42.88%

CAGR/Max DD0.00

CAGR/Mean DD-0.01

EPS (Earnings per Share)

EPS CAGR: 1.61%
EPS Trend: 34.6%

Last SUE: 1.11
Qual. Beats: 2

Revenue

Rev. CAGR: 5.76%
Rev. Trend: 97.8%

Last SUE: 0.95
Qual. Beats: 2

Warnings

Below Avwap Earnings

Tailwinds

Confidence

Seasonality 11.7 years of data

Jan -0.1% 7

Feb +0.9% 10

Mar +1.0% 18

Apr +1.7% 5

May +0.8% 2

Jun -3.2% 35

Jul +3.1% 19

Aug +0.1% 7

Sep -1.6% 15

Oct -0.6% 0

Nov +3.6% 30

Dec -0.8% 14

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CHE Chemed

Chemed Corporation (NYSE: CHE) is a Cincinnati-based holding company operating two distinct businesses: the VITAS segment, which provides hospice and palliative care services across the United States through a multidisciplinary team of physicians, nurses, aides, social workers, clergy, and volunteers, and the Roto-Rooter segment, which delivers plumbing, drain cleaning, excavation, and water restoration services to residential and commercial customers via company-owned branches, independent contractors, and franchisees. Founded in 1970 and publicly listed since 1973, the company combines a regulated healthcare services business with a consumer-facing, asset-light trades services franchise.

The VITAS segment operates within the U.S. hospice and palliative care industry, where the vast majority of patients are aged 65 and older and services are predominantly reimbursed through the Medicare Hospice Benefit, making the segments revenue closely tied to Medicare per-diem payment rates set by the Centers for Medicare & Medicaid Services. The Roto-Rooter segment benefits from a franchise and independent-contractor distribution model, which reduces capital intensity relative to fully company-owned service networks and provides recurring demand from maintenance, emergency repair, and water-damage restoration needs in both residential and commercial properties.

Chemed is classified in the GICS Health Care sector within Health Care Services, and with a market capitalization of roughly $6.7 billion it sits in the mid-cap segment of U.S. equities. Its dual-segment structure across health care and consumer services is relatively uncommon among publicly traded health care companies, giving investors exposure to both a demographic-driven end-of-life care business and a more cyclical, franchise-based plumbing and restoration business.

Headlines to Watch Out For

Medicare hospice reimbursement rate updates drive VITAS margin trajectory
Roto-Rooter revenue surges on severe weather and aging housing infrastructure
Hospice nurse staffing shortages pressure labor costs and admissions growth

Piotroski VR-10 (Strict) 7.0

Net Income: 275.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.20 > 0.02 and ΔFCF/TA -1.13 > 1.0
NWC/Revenue: -1.10% < 20% (prev 9.06%; Δ -10.16% < -1%)
CFO/TA 0.25 > 3% & CFO 390.0m > Net Income 275.0m
Net Debt (434.6m) to EBITDA (431.7m): 1.01 < 3
Current Ratio: 0.91 > 1.5 & < 3
Outstanding Shares: last quarter (13.4m) vs 12m ago -8.10% < -2%
Gross Margin: 30.44% > 18% (prev 33.65%; Δ -3.21% > 0.5%)
Asset Turnover: 157.4% > 50% (prev 146.2%; Δ 11.17% > 0%)
Interest Coverage Ratio: 75.74 > 6 (EBIT TTM 365.3m / Interest Expense TTM 4.82m)

Altman Z'' 8.88

A: -0.02 (Total Current Assets 291.2m - Total Current Liabilities 319.8m) / Total Assets 1.58b
B: 1.95 (Retained Earnings 3.07b / Total Assets 1.58b)
C: 0.22 (EBIT TTM 365.3m / Avg Total Assets 1.65b)
D: 1.11 (Book Value of Equity 830.5m / Total Liabilities 749.1m)
Altman-Z'' = 8.88 = AAA

Beneish M -2.69

DSRI: 0.99 (Receivables 188.6m/184.9m, Revenue 2.60b/2.51b)
GMI: 1.11 (GM 33.65% / 30.44%)
AQI: 1.40 (AQ_t 0.73 / AQ_t-1 0.52)
SGI: 1.03 (Revenue 2.60b / 2.51b)
TATA: -0.07 (NI 275.0m - CFO 390.0m) / TA 1.58b)
Beneish M = -2.69 (Cap -4..+1) = A

What is the price of CHE shares?

As of October 03, 2026, the stock is trading at USD 507.50 with a total of 159,121 shares traded. Over the past week, the price has changed by -0.91%, over one month by -3.15%, over three months by +3.78% and over the past year by +15.42%.

Current recommended Stop Loss: 476.20 (which is 6.2% or 2.4 ATR below the current price).

Is CHE a buy, sell or hold?

Chemed has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy CHE.

StrongBuy: 2
Buy: 1
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the CHE price?

Analysts Target Price	571.6	12.6%

Chemed (CHE) - Fundamental Data Overview as of 30 September 2026

Market Cap USD = 6.72b (6.72b USD * 1.0 USD.USD)
P/E Trailing = 25.7794
P/E Forward = 18.1818
P/S = 2.5903
P/B = 7.8386
P/EG = 1.8169
Revenue TTM = 2.60b USD
EBIT TTM = 365.3m USD
EBITDA TTM = 431.7m USD
Long Term Debt = 91.2m USD (from longTermDebt, two quarters ago)
Short Term Debt = 75.6m USD (from shortTermDebt, last quarter)
Debt = 474.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 145.7m
Net Debt = 434.6m USD (calculated: Debt 474.8m - CCE 40.2m)
Enterprise Value = 7.16b USD (6.72b + Debt 474.8m - CCE 40.2m)
Interest Coverage Ratio = 75.74 (Ebit TTM 365.3m / Interest Expense TTM 4.82m)
EV/FCF = 22.11x (Enterprise Value 7.16b / FCF TTM 323.6m)
FCF Yield = 4.52% (FCF TTM 323.6m / Enterprise Value 7.16b)
FCF Margin = 12.47% (FCF TTM 323.6m / Revenue TTM 2.60b)
Net Margin = 10.60% (Net Income TTM 275.0m / Revenue TTM 2.60b)
Gross Margin = 30.44% ((Revenue TTM 2.60b - Cost of Revenue TTM 1.81b) / Revenue TTM)
Gross Margin QoQ = 30.36% (prev 30.25%)
Tobins Q-Ratio = 4.53 (Enterprise Value 7.16b / Total Assets 1.58b)
Interest Expense / Debt = 1.02% (Interest Expense 4.82m / Debt 474.8m)
Taxrate = 25.51% (94.2m / 369.2m)
NOPAT = 272.1m (EBIT 365.3m * (1 - 25.51%))
Current Ratio = 0.91 (Total Current Assets 291.2m / Total Current Liabilities 319.8m)
Debt / Equity = 0.57 (Debt 474.8m / totalStockholderEquity, last quarter 830.5m)
Debt / EBITDA = 1.01 (Net Debt 434.6m / EBITDA 431.7m)
Debt / FCF = 1.34 (Net Debt 434.6m / FCF TTM 323.6m)
Total Stockholder Equity = 933.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.68% (Net Income 275.0m / Total Assets 1.58b)
RoE = 29.45% (Net Income TTM 275.0m / Total Stockholder Equity 933.6m)
RoCE = 35.64% (EBIT 365.3m / Capital Employed (Equity 933.6m + L.T.Debt 91.2m))
RoIC = 21.01% (NOPAT 272.1m / Invested Capital 1.30b)
WACC = 6.15% (E(6.72b)/V(7.20b) * Re(6.53%) + D(474.8m)/V(7.20b) * Rd(1.02%) * (1-Tc(0.26)))
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.21 | Cagr: -5.76%
[DCF] Terminal Value 73.48% ; FCFF base≈342.7m ; Y1≈306.8m ; Y5≈258.4m
[DCF] Fair Price = 282.4 (EV 4.13b - Net Debt 434.6m = Equity 3.69b / Shares 13.1m; r=8.35% [WACC [floored]]; 5y FCF grow -12.87% → 2.50% )
EPS Correlation: 34.61 | EPS CAGR: 1.61% | SUE: 1.11 | # QB: 2
Revenue Correlation: 97.79 | Revenue CAGR: 5.76% | SUE: 0.95 | # QB: 2
EPS current Quarter (2026-09-30): EPS=6.44 | Chg30d=-0.65% | Revisions=+57% | Analysts=5
EPS current Year (2026-12-31): EPS=25.49 | Chg30d=-0.11% | Revisions=+57% | GrowthEPS=+18.3% | GrowthRev=+7.6%
EPS next Year (2027-12-31): EPS=27.52 | Chg30d=-0.03% | Revisions=+29% | GrowthEPS=+7.9% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +67% (up=11, down=1)